The Committee received an updated submission from Omnicell after the calls for views for this inquiry closed.
The Committee received supplementary evidence from Roche Products Limited after the calls for views closed. This report can be found here.
During the evidence session on 4 February 2020, Jonathan Burton was asked what percentage of prescriptions it was appropriate to query. In his response that was sent in following this session, he refers to a study by the General Medical Council quoting that 1 in 20 prescription items contain either a prescribing on monitoring error. The report can be found here.
During the evidence session on 4 February 2020, Campbell Shimmins referred to the Minor Ailment Study (November 2018) which can be read here. In his follow-up email to the Committee, Mr Shimmins wished to also refer to a study conducted by Aberdeen University around the relative cost, value and outcomes associated with minor illness consultations. This study can be found here.
The Healthcare Distribution Association sent the Committee supplementary evidence before they were due to attend the session on 21 January 2020 to give evidence. Their infographic explaining the medicines supply chain can be found here.
The Committee received supplementary evidence from NHS Fife following the evidence session on 18 February 2020 regarding waste reduction data that was referred to by Claire Fernie during the session.